Home   |   Site Map   |   Contact   |   Search     

Board of Directors

David A. Cory, RPh, MBA
President and Chief Executive Officer, Board Director

David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.

Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.

David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.

Back to Top

Edgar G. Engleman, MD
Managing Partner, Vivo Ventures

Dr. Engleman is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California. Dr. Engleman is Professor of Medicine and Pathology at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, he co-founded Cetus Immune (1981), Genelabs Technologies (1984), National Medical Audit (1985), Dendreon Corporation (1992) and CellGate Technologies (1998). Dr. Engleman currently serves on the boards of several private biotechnology companies. Dr. Engleman received his BA from Harvard University and his MD from Columbia University School of Medicine.

Back to Top

Nina Kjellson
General Partner, InterWest Partners

Ms. Kjellson has been part of InterWest's life sciences team since 2002, focusing primarily on investments in biopharmaceuticals. She is a board member of Alvine Pharmaceuticals, Eiger Biopharmaceuticals, Lycera, Primera Diagnostics, Sequel and Trius Therapeutics. Ms. Kjellson led InterWest's investment in APT Pharmaceuticals and Nereus Pharmaceuticals where she is an observer on the board. Additionally, she is actively engaged with InterWest's investments in AkaRx, Devax, Kanisa, and MacuSight. Prior to joining InterWest, Ms. Kjellson was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused hedge fund. Ms. Kjellson began her career conducting health policy and survey research with the Kaiser Family Foundation. Ms. Kjellson received a BS in human biology from Stanford University.

Back to Top

Jeffrey S. Glenn, MD, PhD
Director, Founder

Dr. Glenn is an Associate Professor of Medicine, Gastroenterology & Hepatology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering.

Dr. Glenn is an author on over 50 scientific articles and book chapters, is an inventor on over 30 issued and pending patent applications, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. His primary research interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies.

Dr. Glenn’s work has focused on the function and cell biology of the hepatitis C virus (HCV) non-structural proteins, and has identified a collection of novel antiviral targets within HCV that can form the basis for new potential antiviral strategies. Dr. Glenn discovered the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses including as a trigger of virus assembly and a target for a promising antiviral treatment. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.

Dr. Glenn received his undergraduate degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization, and both a PhD in Biochemistry and Biophysics and MD from the University of California, San Francisco Medical Scientist Training Program. Dr. Glenn completed an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at Stanford University's School of Medicine.

Back to Top